A rundown of two Phase III head-to-head trials comparing Novo's CagriSema with tirzepatide in adults with type 2 diabetes.
Recap by typeshit. Post by Facebook on Facebook.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
Dr. Omer Awan looks ahead at what the fast rise of GLP-1 drugs could mean for the future of the healthcare system.
A short promo pointing viewers to a full podcast episode about GLP-1 weight loss injections. Thin on detail beyond the teaser.
Loading…